symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ACXP,5.1,-0.844007,546870,66326010,0,1.17-8.82,0.65,"Acurx Pharmaceuticals, Inc.",USD,0001736243,US00510M1045,00510M104,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.acurxpharma.com,"Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.","Mr. David P. Luci CPA, CPA, Esq., J.D.",Healthcare,US,4,917-533-1469,259 Liberty Avenue,Staten Island,NY,10305,,0,https://financialmodelingprep.com/image-stock/ACXP.png,2021-06-25,False,False,True,False,False
